Ashling Wahner

Associate Editor, OncLive

Ashling Wahner joined MJH Life Sciences in 2022. She produces OncLive's podcast, OncLive On Air, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com

Articles

Adjuvant Alectinib Is Associated With a Tolerable Safety Profile in ALK+ NSCLC

September 10th 2024

The safety profile of adjuvant alectinib was tolerable and manageable in ALK-positive NSCLC.

THIO Followed by Cemiplimab Leads to Potential OS Benefit in Pretreated Advanced NSCLC

September 10th 2024

THIO followed by cemiplimab generated a potential overall survival benefit in third-line advanced non–small cell lung cancer.

HER2DX Shows Correlation Between ERBB2 mRNA Levels and Survival in HER2+ Breast Cancer

September 10th 2024

HER2DX showed a strong association between ERBB2 mRNA score and survival outcomes in tumor samples from patients with advanced HER2-positive breast cancer.

Heme & Onc Fellow Board Review Tips 2024

September 9th 2024

Drs Armstrong and Tawagi discuss high-yield oncology and hematology topics to focus on when studying for the 2024 oncology board exams.

Sacituzumab Govitecan Generates Responses With Manageable Safety Profile in ES-SCLC

September 9th 2024

Treatment with sacituzumab govitecan in the second-line setting yielded antitumor activity in patients with extensive-stage small cell lung cancer.

HS-20093 Generates Responses in Pretreated ES-SCLC

September 9th 2024

HS-20093 produced responses in extensive-stage small cell lung cancer after prior platinum-based chemotherapy with or without prior immunotherapy.

Early Data Show Complete Responses With Elraglusib Combination in Ewing Sarcoma

September 9th 2024

Elraglusib plus chemotherapy generated early signals of antitumor activity in pediatric patients with relapsed/refractory Ewing and Ewing-related sarcomas.

RLY-2608/Fulvestrant Yields Early Clinical Activity in PI3Kα-Mutated, HR+/HER2–Breast Cancer

September 9th 2024

RLY-2608 plus fulvestrant generated clinically meaningful PFS outcomes in PI3Kα-mutated, HR-positive, HER2-negative advanced or metastatic breast cancer.

FDA Approves TruSight Oncology Comprehensive Assay As Pan-Tumor Companion Diagnostic

September 9th 2024

The TruSight Oncology Comprehensive Assay has been approved by the FDA with companion diagnostic claims in NSCLC and NTRK-positive solid tumors.

Real-World Outpatient CAR T-Cell Administration Insights Show Improved Safety and Feasibility in NHL

September 9th 2024

Radhika Bansal, MBBS, discusses data showing the safety and feasibility of outpatient CAR T-cell infusion in relapsed/refractory non-Hodgkin lymphoma.

D-VRd Improves MRD-Negativity Rates in Newly Diagnosed, Transplant-Eligible Myeloma

September 6th 2024

D-VRd improved rates of MRD negativity and sustained MRD negativity vs VRd in transplant-eligible, newly diagnosed multiple myeloma.

Dr McGregor on the Updated NCCN Guidelines for Non–Clear Cell RCC

September 6th 2024

Bradley McGregor, MD, discusses the current NCCN guideline recommendations for the treatment of patients with divergent RCC histologies.

Dr Ornstein on the Use of IO/TKI Doublets in Non-ccRCC

September 6th 2024

Moshe Ornstein, MD, MA, discusses the use of first-line IO/TKI doublet regimens in patients with non–clear cell renal cell carcinoma.

Vorasidenib Breaks Through as the First Systemic Therapy for Select Patients With Glioma

September 6th 2024

Seema Nagpal, MD, discusses the significance of the FDA approval of vorasidenib for adult and pediatric patients with IDH1/2-mutant glioma.

Florez Focuses on Patient-Centered NSCLC Biomarker Testing Discussions

September 5th 2024

Dr Florez discusses ways that she helps patients with lung cancer understand the importance of biomarker testing.

Imetelstat Delivers Sustained RBC-TI With No OS Detriment in Lower-Risk MDS

September 5th 2024

Imetelstat sustained red blood cell (RBC) transfusion independence in patients with RBC transfusion–dependent lower-risk myelodysplastic syndrome.

Park and Graff Explore the Evolving Role of CDK4/6 Inhibitors in Metastatic Breast Cancer

September 4th 2024

Drs Park and Graff discuss the evolution of treatment for patients with metastatic HR-positive breast cancer, including the role of CDK4/6 inhibitors.

IBI363 Receives FDA Fast Track Designation for Advanced/Metastatic Melanoma

September 4th 2024

The FDA has granted fast track designation to IBI363 for unresectable advanced or metastatic melanoma after progression on at least 1 line of therapy.

Phase 3 Trial of First-Line IO102-IO103/Pembrolizumab to Continue in Advanced Melanoma

September 4th 2024

The phase 3 IOB-013/KN-D18 trial of IO102-IO103 plus pembrolizumab in advanced melanoma will continue without modifications.

Baseline Radiologic Tumor Burden Is Prognostic for OS in Metastatic ccRCC

September 4th 2024

Rashad Nawfal, MD, discusses the association between radiologic tumor burden and OS in patients with metastatic ccRCC who had received frontline IO.